Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Inclusion Criteria:

* All patients with surgical stage III or IVA endometrial carcinoma per FIGO 2009 staging criteria including clear cell and serous papillary and undifferentiated carcinoma

  * Surgical stage III disease includes those patients with positive adnexa, parametrial involvement, tumor invading the serosa, positive pelvic and/or para-aortic nodes, or vaginal involvement
  * Surgical stage IVA patients with bladder or bowel mucosal involvement, but no spread outside the pelvis
* Patients with FIGO 2009 surgical stage I or II endometrial clear cell or serous carcinoma and with positive peritoneal cytology
* Surgery must have included a hysterectomy and bilateral salpingo-oophorectomy; pelvic lymph node sampling and para-aortic lymph node sampling are optional
* Patients with a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
* White blood cell (WBC) \>= 3,000/mcl
* Absolute neutrophil count (ANC) \>= 1,500/mcl
* Platelet count \>= 100,000/mcl
* Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =\< 2.5 x upper limit of normal (ULN)
* Alkaline phosphatase =\< 2.5 times ULN
* Bilirubin =\< 1.5 times ULN
* Creatinine =\< institutional ULN
* Patients who have met the pre-entry requirements; testing values/results must meet eligibility criteria
* Patients who have signed an approved informed consent and authorization permitting release of personal health information
* Entry into the study is limited to no more than 8 weeks from the date of surgery

Exclusion Criteria:

* Patients with carcinosarcoma
* Patients with recurrent endometrial cancer
* Patients with residual tumor after surgery (any single site) exceeding 2 cm in maximum dimension
* Patients who have had pelvic or abdominal radiation therapy
* Patients with positive pelvic washings as the only extra-uterine disease are NOT eligible if the histology is other than clear cell or papillary serous carcinoma
* Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of active malignancy within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
* Patients with a history of serious co-morbid illness or uncontrolled illnesses that would preclude protocol therapy
* Patients with an estimated survival of less than three months
* Patients with FIGO 2009 stage IVB endometrial cancer
* Patients with parenchymal liver metastases
* Patients who have received prior chemotherapy for endometrial cancer
* Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment